Clinical trials
ALL (Acute B-Lymphoblastic Leukemia) clinical trials
Below are recruiting all (acute b-lymphoblastic leukemia) clinical trials, each written for real people, not researchers. We’re tracking 20 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03911128Recruiting
Treatment protocol for newly diagnosed childhood and young adult ALL
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
AalborgAges birth–45 years - NCT04307576RecruitingPhase 3
Study for newly diagnosed ALL children and young adults
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
BrusselsAges birth–45 years - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT07677878RecruitingPhase 1
Blinatumomab and low-dose DLI after transplant for B-ALL
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
BeijingAges 18–70 - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Birmingham, AlabamaAges 1–30 - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT06307600RecruitingEarly Phase 1
CAR T-Cell Therapy for Relapsed or Refractory B-ALL
This trial tests a new CAR T-cell therapy (called RD06-03) for people whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or hasn't responded to other treatments. It aims to see if the therapy is safe and can help fight the leukemia.
Hefei, AnhuiAges 3–70 - NCT06389305Recruiting
CIK cell therapy for B-cell leukemia after CAR-T failure
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
Beijing, Beijing MunicipalityAges 1–39 - NCT06607419RecruitingPhase 2/Phase 3
Blinatumomab for leftover leukemia in children with B-ALL
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Hefei, AnhuiAges 1 month–18 years - NCT06608342RecruitingPhase 2
Stem cell transplant plus CAR-T for high-risk leukemia
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07297576Recruiting
Sulforaphane to speed blood recovery after cord blood transplant
This trial tests if a natural compound called sulforaphane can help your blood cells recover faster after a cord blood transplant for high-risk blood cancers. If you qualify, you would receive this supplement along with your transplant.
TianjingAges 18 years+ - NCT04836507RecruitingPhase 1/Phase 2
Study of a lab-made cell therapy for lymphoma and leukemia
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT07429461RecruitingEarly Phase 1
SYNCAR-100 for relapsed B-ALL
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Hangzhou, ZhejiangAges 18–75 - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for all (acute b-lymphoblastic leukemia)?
- Yes. Clin2 currently lists 20 recruiting all (acute b-lymphoblastic leukemia) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a all (acute b-lymphoblastic leukemia) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a all (acute b-lymphoblastic leukemia) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.